NCT07131514View on ClinicalTrials.gov

HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Pancreatic Cancer
Interventions
DRUG

HRS-4642+AG +Adebrelimab

HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab will be administrated per dose level in which the patients are assigned.

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Ruijin Hospital

OTHER

NCT07131514 - HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer | Biotech Hunter | Biotech Hunter